Cetuximab.txt Cetuximab CLINICAL USE Monoclonal antibody: Treatment of EGFR-expressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecan-including cytotoxic therapy DOSE IN NORMAL RENAL FUNCTION Initial dose 400 mg/m2 then 250 mg/m2 weekly PHARMACOKINETICS Molecular weight                           :152 000 %Protein binding                           :No data %Excreted unchanged in urine     : minimal Volume of distribution (L/kg)       :1.5–6.2 L/m2 half-life – normal/ESRD (hrs)      :70–100/unchanged DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : Dose as in normal renal function. Use with caution 10 to 20     : Dose as in normal renal function. Use with caution <10           : Dose as in normal renal function. Use with caution DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                :Not dialysed. Dose as in GFR <10 mL/min HD                     :Not dialysed. Dose as in GFR <10 mL/minHDF/high flux   :Not dialysed. Dose as in GFR <10 mL/minCAV/VVHD      :Not dialysed. Dose as in GFR=10–20 mL/min IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugs None known ADMINISTRATION Reconstition– Route IV infusion Rate of Administration 1st dose: 120 minutes Further doses: 60 minutes Maximum infusion rate must not exceed 5 mL/minCommentsAdminister via a 0.2 micrometer in-line filterThe filter may clog and need to be replaced during the infusion OTHER INFORMATION Delayed hypersensitivity reactions may occur and patients should be warned to contact their doctor if this occurs Premedication with an antihistamine is recommended 2% of patients receiving cetuximab developed renal failure Give irinotecan at least 1 hour after the end of cetuximab infusion. Tags: post-by-auto-php Continue Reading Previous Previous post: CUSHINGS SYNDROME .txtNext Next post: Cinacalcet.txt Related News sotalol hydrochloride.txt tazocin.txt